ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

UK Health Body Approves Novartis's Gilenya For MS

ZURICH -(Dow Jones)- The U.K.'s health-cost regulator is backing Novartis's (NVS) pill Gilenya for certain adult patients with highly active relapsing-remitting multiple sclerosis. The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it is recommending Gilenya, or fingolimod, for use on the publicly funded National Health Service. "We are pleased to recommend fingolimod as a treatment option for the specific patient population for whom it has been demonstrated to be cost-effective, providing Novartis applies its proposed discount," NICE Director Carol Longson said, without disclosing the price. Gilenya has been available in the European Union since March 2011 for treating relapsing-remitting MS, the most common type of the disease. The drug was approved in the U.S. in 2010. Novartis hopes the drug will become one of the leading treatments in the multibillion-dollar market for treating MS due to its easy oral use. "Novartis welcomes this final decision from NICE, which will allow appropriate patients with highly active relapsing-remitting MS to have access to Gilenya under the NHS in England and Wales," the company said in a statement, adding that it "remains committed to engaging with reimbursement authorities with the goal of ensuring that appropriate patients will have access to the treatment." Last week, EU and US regulators requested stronger label warnings for Gilenya after conducting reviews of the pill's safety, following reports of heart problems and the death of a patient. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
05/03/201608:30:00Shannon Klinger to Replace Eric Cornut as Novartis's Ethics Officer
05/03/201608:19:00Shannon Klinger to Replace Eric Cornut as Novartis's Ethics Officer
04/29/201604:50:00AstraZeneca's Investment Eats Into Profit
04/28/201616:40:00Amgen Profit Rises 17%, Guidance Raised
04/27/201608:20:00GlaxoSmithKline Sees First-Quarter Profit Fall
04/26/201608:10:00Eli Lilly Revenue Boosted By New Drug Sales
04/22/201603:03:00Novartis Feels the Effect Of Drop in Gleevec Sales -- WSJ
04/21/201608:29:00Novartis Earnings Fall on Slide in Cancer-Drug Sales -- 2nd Update
04/21/201603:50:00Novartis Earnings Fall on Slide in Cancer-Drug Sales --Update
04/21/201602:10:00Novartis Earnings Fall on Slide in Cancer-Drug Sales
04/21/201602:03:00Novartis Earnings Fall on Slide in Cancer-Drug Sales
04/18/201610:31:00Novartis AG 1Q 2016 -- Forecast
04/15/201617:00:00Costco, J&J Spar Over Contact-Lens Business
04/15/201616:15:00Costco, J&J Spar Over Contact-Lens Business
04/08/201605:10:00AstraZeneca, Eli Lilly in Final Stage of Testing Alzheimer's...
04/05/201617:50:00FDA Approves Rheumatoid Arthritis Biosimilar
03/29/201614:40:00Sun Pharma to Buy Japanese Brands From Novartis in $293 Million...
03/17/201604:20:00GSK CEO Andrew Witty to Retire
03/16/201616:00:00Novartis Heart-Failure Pill Falls Short of Sales Expectations
02/29/201619:02:00Anacor Pharmaceuticals' Revenue Doubles But Misses Views

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad